The Tufts Center for the Study of Drug Development issued their latest estimate for the cost of developing a new drug: an eye-popping $2.6 billion. The estimate, made by the independent, nonprofit research group, is based on data provided by ten pharma companies on 106 randomly selected drugs. It includes out-of-pocket costs of $1.4 billion and another $1.1 billion in time costs—“the expected returns that investors forego while a drug is in development.” Post-approval costs add another $312 million. The 145% increase from their previous estimate, done in 2003, is attributed to the increased complexity of clinical trials and health assessments, not to regulatory delays.
Rights and permissions
About this article
Cite this article
New drug costs soar to $2.6 billion. Nat Biotechnol 32, 1176 (2014). https://doi.org/10.1038/nbt1214-1176b
Published:
Issue Date:
DOI: https://doi.org/10.1038/nbt1214-1176b
This article is cited by
-
Repurposing clinically approved cephalosporins for tuberculosis therapy
Scientific Reports (2016)